Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Amazon Explores AI Content Marketplace With Media Publishers 
PRESS RELEASE
Active Biotech has received a waiver (exemption) from its commitment to the bank that finances the company's property in Lund that the company's liquidity should never fall below SEK 30 million.
This exemption applies until and including February 27, 2018, during which time the company must produce a sale of the property at a value that generates a liquidity supplement that meets the requirements for going concern, i.e. liquidity for twelve months of operation.
Unless this or any other solution is found before February 27, 2018, the company will not have funding for the coming twelve-month period.
Lund, December 20, 2017
Active Biotech AB (publ)
Helén Tuvesson
President and CEO
For further information, please contact:
Mats Arnhög, Chairman of the Board
Tel. +46 8 545 03 770
Mobile +46 705 91 50 96
Helén Tuvesson, President and CEO
Tel. +46 46 19 21 56
Hans Kolam, CFO
Tel. +46 46 19 20 44
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties is in development for neurodegenerative diseases in partnership with Teva Pharmaceutical Industries Ltd. ANYARA, an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 15.00 p.m. CET on December 20, 2017.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/e0f4d0fc-c523-4fba-8f6c-acaaf567e7a2
